Finesse with Linzess

Why Ironwood's Linzess profits are growing faster than sales

Thanks to a relatively flat expense line in 2Q16, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) almost doubled proceeds from its Linzess linaclotide deal with Allergan plc (NYSE:AGN). Going forward, the biotech expects to be able to deploy an expanding

Read the full 372 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE